MOLNNasdaq

MOLECULAR PARTNERS AG

Healthcare·Oncology·Commercial·Schlieren, Switzerland
OncologyOphthalmologyRespiratory

MOLECULAR PARTNERS AG (MOLN): 34 pipeline candidates · 1 upcoming catalyst · 3 clinical trials. Updated within the last hour.

7.9/10

BioSniper Score

4-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health9.6

D/E 0.27 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth10.0

34 candidates

Catalyst Momentum2.0

1 upcoming, next in ~714d

Insider SignalN/A

N/A

A transparent, data-derived signal for MOLECULAR PARTNERS AGacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$154.2M

Cash

$82.7M

Quarterly Burn

—

Runway

—

Revenue

—

Cash Runway vs Catalysts

Upcoming catalyst timeline.

Today~26 mo out
Catalyst within runway

Pipeline (34 candidates)

DrugPhase
[212pb]pb-mp0712Phase 1/Phase 2
150 ivtPhase 3
amplichip cyp450 test—
amplichip cyp450 test—
amplicor mycobacterium tuberculosis test—
cobas ampliprep/cobas taqman cytomegalovirus testApproved
cobas ampliprep/cobas taqman hcv test v2.0—
cobas braf v600 mutation test—
cobas hpv test—
eyleaPhase 3

Showing 10 of 34 candidates. Sign up for full pipeline.

Upcoming Catalysts (1)

Phase3_ToplinePhase 3 Topline: A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of

Clinical data readout — efficacy/safety results are a high-impact catalyst.

68.6% historical Phase 3 primary-endpoint success rate (n=363)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

4

Total value held

$14.2M

HolderSharesValue
suvretta capital management, llc2,221,494$8.8M
bvf inc/il1,353,968$5.4M
smartharvest portfolios, llc15,543$62K
morgan stanley367$1K
3 clinical trials·CEO: Dr. Patrick Amstutz Ph.D.

Frequently asked questions

How many drug candidates are in MOLECULAR PARTNERS AG's pipeline?

MOLECULAR PARTNERS AG (MOLN) has 34 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is MOLECULAR PARTNERS AG's lead drug candidate?

MOLECULAR PARTNERS AG's most advanced tracked candidate is [212pb]pb-mp0712 (Phase 1/Phase 2) for Large Cell Neuroendocrine Carcinoma.

What is MOLECULAR PARTNERS AG's next catalyst?

MOLECULAR PARTNERS AG's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of " — expected June 1, 2028.

What is MOLECULAR PARTNERS AG's market capitalization?

MOLECULAR PARTNERS AG's market capitalization is approximately $154.2M.

Who is the CEO of MOLECULAR PARTNERS AG?

Dr. Patrick Amstutz Ph.D. is the chief executive officer of MOLECULAR PARTNERS AG (MOLN).

Get the full picture on MOLECULAR PARTNERS AG

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar